Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imetelstat in Children With Recurrent Brain Tumors
NCT01836549Phase 2Terminated
- Sponsor
- Pediatric Brain Tumor Consortium
- Start
- Mar 2013
- Primary completion
- Apr 2016
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imetelstat in glioma, ependymoma and diffuse intrinsic pontine glioma (DIPG), sponsored by Pediatric Brain Tumor Consortium. Primary endpoints: Reduction in Telomerase Activity up to 30 days and Objective Response Rate at 6 months. Started Mar 2013; status: terminated.
02
Drugs
imetelstat
03
Conditions
gliomaependymomadiffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT01836549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01836549.